p.105 抽出テキスト
471. Biddinger KJ, Emdin CA, Haas ME, Wang M, Hindy G, Ellinor PT, et al. Association of habitual alcohol intake with risk of cardiovascular disease. JAMA Netw Open 2022;5: e223849. https://doi.org/10.1001/jamanetworkopen.2022.3849 472. Tully PJ, Ang SY, Lee EJ, Bendig E, Bauereiß N, Bengel J, et al. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev 2021;12:CD008012. https://doi.org/10.1002/14651858. CD008012.pub4 473. Kraus WE, Powell KE, Haskell WL, Janz KF, Campbell WW, Jakicic JM, et al. Physical activity, all-cause and cardiovascular mortality, and cardiovascular disease. Med Sci Sports Exerc 2019;51:1270–81. https://doi.org/10.1249/MSS.0000000000001939 474. Hupin D, Roche F, Gremeaux V, Chatard J-C, Oriol M, Gaspoz J-M, et al. Even a lowdose of moderate-to-vigorous physical activity reduces mortality by 22% in adults aged ≥60 years: a systematic review and meta-analysis. Br J Sports Med 2015;49:1262–7. https://doi.org/10.1136/bjsports-2014-094306 475. Arem H, Moore SC, Patel A, Hartge P, Berrington de Gonzalez A, Visvanathan K, et al. Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship. JAMA Intern Med 2015;175:959–67. https://doi.org/10. 1001/jamainternmed.2015.0533 476. Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med 2020;54:1451–62. https://doi.org/10.1136/bjsports-2020-102955 477. O’Donovan G, Lee IM, Hamer M, Stamatakis E. Association of “weekend warrior” and other leisure time physical activity patterns with risks for all-cause, cardiovascular disease, and cancer mortality. JAMA Intern Med 2017;177:335–42. https://doi.org/10. 1001/jamainternmed.2016.8014 478. Jakicic JM, Kraus WE, Powell KE, Campbell WW, Janz KF, Troiano RP, et al. Association between bout duration of physical activity and health: systematic review. Med Sci Sports Exerc 2019;51:1213–9. https://doi.org/10.1249/MSS.0000000000001933 479. Ekelund U, Tarp J, Steene-Johannessen J, Hansen BH, Jefferis B, Fagerland MW, et al. Dose-response associations between accelerometry measured physical activity and sedentary time and all cause mortality: systematic review and harmonised meta-analysis. BMJ 2019;366:l4570. https://doi.org/10.1136/bmj.l4570 480. Anderson L, Thompson DR, Oldridge N, Zwisler A-D, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2016;1:CD001800. https://doi.org/10.1002/14651858.CD001800.pub3 481. Santiago de Araujo Pio C, Marzolini S, Pakosh M, Grace SL. Effect of cardiac rehabilitation dose on mortality and morbidity: a systematic review and meta-regression analysis. Mayo Clin Proc 2017;92:1644–59. https://doi.org/10.1016/j.mayocp.2017.07.019 482. Salzwedel A, Jensen K, Rauch B, Doherty P, Metzendorf M-I, Hackbusch M, et al. Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease patients treated according to contemporary evidence based medicine: update of the Cardiac Rehabilitation Outcome Study (CROS-II). Eur J Prev Cardiol 2020;27: 1756–74. https://doi.org/10.1177/2047487320905719 483. Dibben G, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler A-D, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2021;11:CD001800. https://doi.org/10.1002/14651858.CD001800.pub4 484. Ambrosetti M, Abreu A, Corra U, Davos CH, Hansen D, Frederix I, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: from knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol 2020;28:460–95. https://doi.org/10.1177/2047487320913379 485. Hansen D, Abreu A, Ambrosetti M, Cornelissen V, Gevaert A, Kemps H, et al. Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: why and how: a position statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol 2022;29:230–45. https://doi.org/10.1093/eurjpc/zwab007 486. Hansen D, Niebauer J, Cornelissen V, Barna O, Neunhäuserer D, Stettler C, et al. Exercise prescription in patients with different combinations of cardiovascular disease risk factors: a consensus statement from the EXPERT working group. Sports Med 2018; 48:1781–97. https://doi.org/10.1007/s40279-018-0930-4 487. Abell B, Glasziou P, Hoffmann T. The contribution of individual exercise training components to clinical outcomes in randomised controlled trials of cardiac rehabilitation: a systematic review and meta-regression. Sports Med Open 2017;3:19. https://doi.org/10. 1186/s40798-017-0086-z 488. Sanchez-Delgado JC, Camargo Sepulveda DC, Cardona Zapata A, Franco Pico MY, Santos Blanco LM, Jácome Hortúa AM, et al. The effects of maintenance cardiac rehabilitation: a systematic review. J Cardiopulm Rehabil Prev 2020;40:224–44. https:// doi.org/10.1097/HCR.0000000000000520 489. Piepoli MF, Corra U, Dendale P, Frederix I, Prescott E, Schmid JP, et al. Challenges in secondary prevention after acute myocardial infarction: a call for action. Eur J Prev Cardiol 2016;23:1994–2006. https://doi.org/10.1177/2047487316663873 490. Gomes-Neto M, Duraes AR, Reis H, Neves VR, Martinez BP, Carvalho VO. High-intensity interval training versus moderate-intensity continuous training on exercise capacity and quality of life in patients with coronary artery disease: a systematic review and meta-analysis. Eur J Prev Cardiol 2017;24:1696–707. https://doi.org/10. 1177/2047487317728370 491. Franssen WMA, Franssen G, Spaas J, Solmi F, Eijnde BO. Can consumer wearable activity tracker-based interventions improve physical activity and cardiometabolic health in patients with chronic diseases? A systematic review and meta-analysis of randomised controlled trials. Int J Behav Nutr Phys Act 2020;17:57. https://doi.org/10.1186/s12966- 020-00955-2 492. Santiago de Araujo Pio C, Chaves GS, Davies P, Taylor RS, Grace SL. Interventions to promote patient utilisation of cardiac rehabilitation. Cochrane Database Syst Rev 2019; 2:CD007131. https://doi.org/10.1002/14651858.CD007131.pub4 493. Anderson L, Sharp GA, Norton RJ, Dalal H, Dean SG, Jolly K, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev 2017;6:CD007130. https://doi.org/10.1002/14651858.CD007130.pub4 494. Jin K, Khonsari S, Gallagher R, Gallagher P, Clark AM, Freedman B, et al. Telehealth interventions for the secondary prevention of coronary heart disease: a systematic review and meta-analysis. Eur J Cardiovasc Nurs 2019;18:260–71. https://doi.org/10.1177/ 1474515119826510 495. Cruz-Cobo C, Bernal-Jimenez MA, Vazquez-Garcia R, Santi-Cano MJ. Effectiveness of mHealth interventions in the control of lifestyle and cardiovascular risk factors in patients after a coronary event: systematic review and meta-analysis. JMIR Mhealth Uhealth 2022;10:e39593. https://doi.org/10.2196/39593 496. Hamilton SJ, Mills B, Birch EM, Thompson SC. Smartphones in the secondary prevention of cardiovascular disease: a systematic review. BMC Cardiovasc Disord 2018;1:25. https://doi.org/10.1186/s12872-018-0764-x 497. Kissel CK, Nikoletou D. Cardiac rehabilitation and exercise prescription in symptomatic patients with non-obstructive coronary artery disease—a systematic review. Curr Treat Options Cardiovasc Med 2018;20:78. https://doi.org/10.1007/s11936-018-0667-2 498. Keteyian SJ, Brawner CA, Savage PD, Ehrman JK, Schairer J, Divine G, et al. Peak aerobic capacity predicts prognosis in patients with coronary heart disease. Am Heart J 2008;156:292–300. https://doi.org/10.1016/j.ahj.2008.03.017 499. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290:86–97. https://doi.org/10.1001/jama.290.1.86 500. Held C, Hadziosmanovic N, Aylward PE, Hagström E, Hochman JS, Stewart RAH, et al. Body mass index and association with cardiovascular outcomes in patients with stable coronary heart disease—a STABILITY substudy. J Am Heart Assoc 2022;11:e023667. https://doi.org/10.1161/JAHA.121.023667 501. Stewart RA, Wallentin L, Benatar J, Danchin N, Hagström E, Held C, et al. Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease. Eur Heart J 2016;37:1993–2001. https:// doi.org/10.1093/eurheartj/ehw125 502. Stewart RAH, Held C, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, et al. Physical activity and mortality in patients with stable coronary heart disease. J Am Coll Cardiol 2017;70:1689–700. https://doi.org/10.1016/j.jacc.2017.08.017 503. Artinian NT, Fletcher GF, Mozaffarian D, Kris-Etherton P, Van Horn L, Lichtenstein AH, et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation 2010;122:406–41. https://doi.org/10.1161/ CIR.0b013e3181e8edf1 504. Ferrari R, Pavasini R, Camici PG, Crea F, Danchin N, Pinto F, et al. Anti-anginal drugsbeliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J 2019;40:190–4. https://doi.org/10.1093/eurheartj/ehy504 505. Belsey J, Savelieva I, Mugelli A, Camm AJ. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: a systematic review and meta-analysis. Eur J Prev Cardiol 2015;22:837–48. https://doi.org/10.1177/2047487314533217 506. Pavasini R, Camici PG, Crea F, Danchin N, Fox K, Manolis AJ, et al. Anti-anginal drugs: systematic review and clinical implications. Int J Cardiol 2019;283:55–63. https://doi. org/10.1016/j.ijcard.2018.12.008 507. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K; INITIATIVE Investigators. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529–36. https://doi.org/10.1093/eurheartj/ehi586 508. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007;67:393–405. https://doi.org/10.2165/00003495-200767030-00005 509. Fox K, Ford I, Steg PG, Tardif J-C, Tendera M, Ferrari R, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014;371:1091–9. https://doi.org/10.1056/NEJMoa1406430 510. Sorbets E, Steg PG, Young R, Danchin N, Greenlaw N, Ford I, et al. Beta-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J 2019;40:1399–407. https://doi.org/10.1093/eurheartj/ehy811 511. Steg PG, Greenlaw N, Tendera M, Tardif J-C, Ferrari R, Al-Zaibag M, et al. Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry. JAMA Intern Med 2014;174:1651–9. https://doi. org/10.1001/jamainternmed.2014.3773 512. Ford TJ, Berry C. Angina: contemporary diagnosis and management. Heart 2020;106: 387–98. https://doi.org/10.1136/heartjnl-2018-314661 ESC Guidelines 3519 Downloaded from academic.oup.com/eurheartj/article/45/36/3415/7743115 by guest on 07 October 2026